← Leaderboards
Gregory Jaye Bix
Tulane University Of Louisiana
$10,514,161
Attributed
$15,746,523
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2010–24$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,746,523 · 11
By mechanism
R01$8,728,185 · 4
RF1$4,946,939 · 2
R21$2,071,399 · 5
Top collaborators
- Emmanuel Pinteaux7 shared
- Jean-Pyo Lee6 shared
- D. Richard Milner3 shared
- Tione Buranda2 shared
- Jerome Badaut1 shared
- Roxana Octavia Carare1 shared
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Roxana Octavia Carare$191,300
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainStrokePerlecanExtracellular MatrixIn VitroPost StrokeProteinsIntegrinsProtein FragmentInfarctionIschemic StrokeEndothelial CellsRepairedStroke TherapyCause Of DeathPublic Health RelevanceKnockout MiceBlood VesselsInjuryAngiogenesisInnovationIn VivoNeuronsBlood - Brain Barrier Anatomy
Grant awards (40)
Investigating the Role and the therapeutic potential of Perlecan in experimental vascular dementia$2,573,724
RF1 · FY2024 · NS · contact PI
Investigating the role of Alpha5Beta1 integrin in cognitive dysfunction$119,115
RF1 · FY2024 · AG · contact PI
Investigating the role and therapeutic potential of the alpha5beta1 integrin in risk factors for COVID-19-associated cognitive impairment$2,254,100
RF1 · FY2023 · AG · contact PI
Combination treatment of ischemic stroke with perlecan DV and neural stem cells$305,122
R01 · FY2023 · NS
Combination treatment of ischemic stroke with perlecan DV and neural stem cells$150,622
R01 · FY2023 · NS
Combination treatment of ischemic stroke with perlecan DV and neural stem cells$484,513
R01 · FY2022 · NS
Perlecan Domain V as a therapeutic VCID strategy for the clearance of amyloid beta from the brain in cerebral amyloid angiopathy$382,600
R21 · FY2022 · NS · contact PI
Interleukin-1 alpha as a novel treatment for ischemic stroke$285,444
R01 · FY2022 · NS · contact PI
Combination treatment of ischemic stroke with perlecan DV and neural stem cells$480,784
R01 · FY2021 · NS
Interleukin-1 alpha as a novel treatment for ischemic stroke$288,580
R01 · FY2021 · NS · contact PI
Combination treatment of ischemic stroke with perlecan DV and neural stem cells$476,441
R01 · FY2020 · NS
Interleukin-1 alpha as a novel treatment for ischemic stroke$290,342
R01 · FY2020 · NS · contact PI
Combination treatment of ischemic stroke with perlecan DV and neural stem cells$481,540
R01 · FY2019 · NS
Perlecan therapy for white matter and cognitive impairment in closed head injury with long-term dysfunction (CHILD)$375,971
R21 · FY2019 · NS · contact PI
Alpha5Beta1 Integrin inhibition as a Profound Blood-Brain Barrier Stabilizing Neuroprotective Stroke Therapy$329,219
R01 · FY2019 · NS · contact PI
Interleukin-1 alpha as a novel treatment for ischemic stroke$315,109
R01 · FY2019 · NS · contact PI
Alpha5Beta1 Integrin inhibition as a Profound Blood-Brain Barrier Stabilizing Neuroprotective Stroke Therapy$329,219
R01 · FY2018 · NS · contact PI
Interleukin-1 alpha as a novel treatment for ischemic stroke$297,352
R01 · FY2018 · NS · contact PI
The Role of Perlecan Domain V in Vascular Dementia$169,254
R01 · FY2018 · NS · contact PI
The Role of Perlecan Domain V in Vascular Dementia$159,965
R01 · FY2018 · NS · contact PI
Alpha5Beta1 Integrin inhibition as a Profound Blood-Brain Barrier Stabilizing Neuroprotective Stroke Therapy$329,219
R01 · FY2017 · NS · contact PI
The Role of Perlecan Domain V in Vascular Dementia$329,219
R01 · FY2017 · NS · contact PI
Vascular protection via alpha5beta1 integrin inhibition during neuroinflammation$230,125
R21 · FY2017 · NS
Alpha5Beta1 Integrin inhibition as a Profound Blood-Brain Barrier Stabilizing Neuroprotective Stroke Therapy$329,219
R01 · FY2016 · NS · contact PI
The Role of Perlecan Domain V in Vascular Dementia$329,219
R01 · FY2016 · NS · contact PI
Vascular protection via alpha5beta1 integrin inhibition during neuroinflammation$301,375
R21 · FY2016 · NS
The Role of Perlecan Domain V in Vascular Dementia$329,219
R01 · FY2015 · NS · contact PI
Alpha5Beta1 Integrin inhibition as a Profound Blood-Brain Barrier Stabilizing Neuroprotective Stroke Therapy$328,946
R01 · FY2015 · NS · contact PI
Use of IL-1alpha to Promote Angiogenesis and Functional Recovery After Experiment$163,531
R21 · FY2015 · NS · contact PI
Alpha5Beta1 Integrin inhibition as a Profound Blood-Brain Barrier Stabilizing Neuroprotective Stroke Therapy$20,000
R01 · FY2015 · NS · contact PI
The Role of Perlecan Domain V in Vascular Dementia$328,307
R01 · FY2014 · NS · contact PI
Perlecan Domain V is a Novel Promoter of Brain Repair after Stroke$315,163
R01 · FY2014 · NS · contact PI
Use of IL-1alpha to Promote Angiogenesis and Functional Recovery After Experiment$208,334
R21 · FY2014 · NS · contact PI
Neuronal Regeneration of Stroked Brain with Perlecan Domain V$185,047
R21 · FY2014 · NS · contact PI
Perlecan Domain V is a Novel Promoter of Brain Repair after Stroke$307,205
R01 · FY2013 · NS · contact PI
Neuronal Regeneration of Stroked Brain with Perlecan Domain V$224,416
R21 · FY2013 · NS · contact PI
Perlecan Domain V is a Novel Promoter of Brain Repair after Stroke$243,300
R01 · FY2012 · NS · contact PI
Perlecan Domain V is a Novel Promoter of Brain Repair after Stroke$67,573
R01 · FY2012 · NS · contact PI
Perlecan Domain V is a Novel Promoter of Brain Repair after Stroke$310,873
R01 · FY2011 · NS · contact PI
Perlecan Domain V is a Novel Promoter of Brain Repair after Stroke$317,217
R01 · FY2010 · NS · contact PI